HSBC initiated coverage of Agilent (A) with a Buy rating and $180 price target Agilent is a global leader in life sciences and diagnostics, and its is well positioned for sustained earnings growth, the analyst tells investors in a research note. The firm likes the shares into the ongoing liquid chromatography and mass spectrometry replacement cycle.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A: